---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-25-037596"
form_type: "8-K"
ticker: "MDGL"
cik: "0001157601"
company_name: "MADRIGAL PHARMACEUTICALS, INC."
filed_at: "2025-08-05T23:59:59+00:00"
generated_at: "2026-05-17T20:27:47.320552+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Madrigal Q2 2025: Rezdiffra sales $212.8M, 23k patients; new patent to 2045; $500M credit

## Summary
- Q2 2025 Rezdiffra net sales $212.8M (vs $14.6M prior year); >23,000 patients on therapy as of June 30, 2025.
- New U.S. patent (No. 12,377,104) covers Rezdiffra weight-threshold dosing; expires Feb 4, 2045 (previously Sept 30, 2044).
- Licensed global rights to oral GLP-1 candidate SYH2086 from CSPC Pharma; enters clinic H1 2026 for MASH combination.
- Secured $500M senior secured credit facility with Blue Owl: $350M initial term loan, $150M delayed draw, plus up to $250M incremental.
- Positive CHMP opinion for Rezdiffra in Europe; EC decision expected Aug 2025; would be first MASH therapy in EU.

## SEC filing metadata
- accession: 0001628280-25-037596
- form_type: 8-K
- ticker: MDGL
- cik: 0001157601
- company_name: MADRIGAL PHARMACEUTICALS, INC.
- filed_at: 2025-08-05T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1157601/000162828025037596/0001628280-25-037596-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1157601/000162828025037596/mdgl-20250805.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-25-037596
- JSON: https://secwatch.observer/filing/0001628280-25-037596.json
- Plain text: https://secwatch.observer/filing/0001628280-25-037596.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.